psa Flashcards
(85 cards)
Donepezil (anticholinesterase inhb)
Bradycardia
Co-beneldopa (bensarazide hydrochloride and levodopa)
Hallucinations
Anxiety
(Rare- leucopenia)
Monitoring for Pramipexole
BP - risk of postural hypotension
Serious SE of Lamotrigine
Stevens Johnson syndrome - rash within 8 weeks of treatment
Risk factor drugs for SJS
Anti-epileptics - Carbamazepine
Allopurinol
Sulfonamides
Anti-fungals- Terbinafine
SE of PPIs
- Low Mg
- Low Na+
- Osteoprosis, #risk
- Microscopic colitis
- C. diff infections (proliferation of C.diff spores due to reduced gastric acid production)
Digoxin toxicity
Can be precipitated by hypokalaemia (doesn’t compete with potassium for ATP-ase pump), but what other factors?
Why does this happen - related to MOA?
* Symptoms/ adverse effects
* Sign on ECG of digoxin induced changes (not necessarily toxicity)?
* Mx
- Digoxin toxicity triggers: electrolyte imbalance, renal failure, age, drugs (amiodarone and ones causing hypokalaemia eg chlortalidone - thiazide like diuretic)
- MOI: inhibitsNa+/K+ ATPase pump by competing with potassium so lower levels of potassium increase its effect
- High potassium reduces its efficacy/risk of treatment failure
- N&V, confusion, yellow-green vision (xanthopsia), drowsiness, diarrhoea
- Arrythmias - Bradycardia, AV block
- ECG: backwards tick - ST segment
- Mx: Digiband, monitor K+, correct arrythmias
Most likely SSRI to cause QT prolongation and torsades de pointes
Citalopram
drugs prolonging QT interval (risk of torsades de pointes - polymorphic VT)
- Methadone
- Odansetron
- Digoxin
- Antipsychotics - Haloperidol/Risperidone
- SSRIs - Fluoexeteine
Mirtazepine:
Class
MOA
Benefit over other antidepressants
NaSSA
Noradrenaline and specific serotinergic antidepressant
Increases levels of NA and serotonin in the brain
Helps with insomina, poor appetite, reduced sexual side effects (libido)
Ticagrelor SE
Dyspnoea
Dyspepsia
Dizziness
Diarrhoea
Gout
Monitoring:
IV Iron Dextran
Blood pressure
Monitoring:
Ethambutol
(eye-thambutol)
- Visual acuity
Monitoring for beneficial effects:
Furosemide
Weight
(overall loss of potassium with furosemide but not most accurate way to assess diuretic effect/volume loss)
Monitoring for beneficial effects:
Factor XA inhibitors (apixaban)
patient reports of bruising
Converting digoxin from IV to oral (via feeding tube)
Increase dose by 20-33% due to oral bioavailability
Monitoring requirements for bisphosphonates?
What has to be corrected before starting treatment?
- serum calcium
- calcium or vitamin d deficiency
treatment of PE: considerations for patients with cancer
Dalteparin sodium / Tinzaparin
CANCER - find in “Fragmin single dose syringe” –>
- “in patients with solid tumours”
- by weight categories
Also pregnant patients
note these extra considerations in the question stem!
Hypercalcaemia management
Aggressive fluid therapy
if hypotensive - fluid challenge
if not hypotensive:
4-6litres of 0.9 % NaCl over 24 hour period
E.g. 500ml over 2 hours
CYP450 Enzymes
Typical substrates
Warfarin
OCP
Statins
SSRI
Amitryptiline, codeine
CYP 450
Inhibitors (risk of toxicity) - SICK FACES
Sulfonamides
Isoniazid
Cimetidine
Ketoconazole
Fluconazole
Alchohol, Amiodarone
Cipro
Erythro
Sodium valproate
CYP 450
Inducers (risk of treatment failure) - CRAP GPS drink grapefruit juice
Carbamazepine
Rifampicin
Alcohol (chronic)
Phenytoin
Griseofulvin
Phenobarbitol
St John’s wort, steroids
+ grapefruit juice!
Hydroxychloroquine (DMARD)
main AE
(bulls eye) retinopathy
risk of blindness
measure visual acuity/annual screening/need opthal review before